Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis

Background Oral 5‐aminosalicylic (5‐ASA) preparations were intended to avoid the adverse effects of sulfasalazine (SASP) while maintaining its therapeutic benefits. Previously, it was found that 5‐ASA drugs were more effective than placebo but had a statistically significant therapeutic inferiority relative to SASP. This updated review includes more recent studies and evaluates the effectiveness, dose‐responsiveness, and safety of 5‐ASA...